Biolinq


Develops a needle-free, intradermal continuous glucose monitoring microsensor with an on-device color-changing indicator and a mobile app. The system collects glucose and physiologic data (activity, sleep) via integrated microsensors and motion/light sensors, provides real-time qualitative feedback on glucose range, and offers app-based trend analysis. The device is FDA cleared for use in adults 22 years and older who are not on insulin.

Industries

Biotechnology
Health Care
Medical Device
Wearables

Nr. of Employees

medium (51-250)

Biolinq

San Diego, California, United States


Patents

Continuous analyte monitoring system with microneedle array

US-12765840-B2

View Details

Method for improved sensor sensitivity of a microneedle-based continuous analyte monitoring system

US-12629060-B2

View Details

Methods for achieving an isolated electrical interface between an anterior surface of a microneedle structure and a posterior surface of a support structure

US-12605100-B2

View Details

Method and system for confirmation of microneedle-based analyte-selective sensor insertion into viable tissue via electrical interrogation

US-12599337-B1

View Details

Solid-state substrate-integrated reference electrode and counter electrode

US-12582337-B2

View Details

Sensor assembly of a microneedle array-based continuous analyte monitoring device

US-12507921-B2

View Details
View All Patents

Products

Autonomous needle-free intradermal continuous glucose microsensor with on-device LED indicator

A wearable intradermal microsensor that continuously measures glucose and displays qualitative time-in-range via a color-changing LED, while also recording activity and ambient light for correlation in a mobile app.

Expertise Areas

  • Continuous glucose monitoring
  • Wearable sensor development
  • Physiologic data analytics
  • Multimodal sensing (activity and sleep)
  • Show More (2)

Key Technologies

  • Continuous intradermal glucose sensing
  • Micro-scale sensor arrays
  • Accelerometer-based activity tracking
  • Ambient light sensing
  • Show More (2)

News & Updates

The time-in-range intradermal microsensor system received FDA clearance for use as a qualitative glucose range monitoring device in adults 22 years and older not on insulin.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.